{"id":55500,"date":"2026-01-26T20:40:46","date_gmt":"2026-01-26T12:40:46","guid":{"rendered":"https:\/\/flcube.com\/?p=55500"},"modified":"2026-01-26T20:40:47","modified_gmt":"2026-01-26T12:40:47","slug":"eisai-biogens-leqembi-autoinjector-wins-fda-priority-review-for-weekly-alzheimers-dosing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55500","title":{"rendered":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing"},"content":{"rendered":"\n<p><strong>Eisai Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO:\u202f4523<\/a>) and <strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ:\u202fBIIB<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has accepted for review a <strong>Supplemental Biologics License Application (sBLA)<\/strong> for <strong>LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI)<\/strong> \u2013 branded <strong>LEQEMBI IQLIK<\/strong> \u2013 as a <strong>once\u2011weekly starting dose<\/strong> for early Alzheimer\u2019s disease, with a <strong>PDUFA action date of May\u202f24,\u202f2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>LEQEMBI IQLIK (lecanemab\u2011irmb subcutaneous autoinjector)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>sBLA (Supplemental Biologics License Application)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Priority Review<\/td><\/tr><tr><td><strong>PDUFA Date<\/strong><\/td><td>May\u202f24,\u202f2026<\/td><\/tr><tr><td><strong>Current IV Status<\/strong><\/td><td>Approved (bi\u2011weekly IV infusion)<\/td><\/tr><tr><td><strong>Proposed Regimen<\/strong><\/td><td>Once\u2011weekly 500\u202fmg SC (two 250\u202fmg injections)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-administration-advantage\">Drug Profile &amp; Administration Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Anti\u2011amyloid beta (A\u03b2) protofibril antibody<\/strong> that clears toxic amyloid plaques in early Alzheimer\u2019s disease<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Bi\u2011weekly <strong>IV infusion<\/strong> (1\u2011hour clinic visit)<\/li>\n\n\n\n<li><strong>LEQEMBI IQLIK Innovation:<\/strong> <strong>Subcutaneous autoinjector<\/strong> enabling <strong>home administration<\/strong> by patients or caregivers<\/li>\n\n\n\n<li><strong>Clinical Benefit:<\/strong> Weekly SC dosing achieves <strong>equivalent drug exposure<\/strong> to bi\u2011weekly IV with <strong>similar clinical and biomarker efficacy<\/strong><\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> <strong>&lt;2\u202f% incidence<\/strong> of systemic injection\/infusion\u2011related reactions (comparable to IV)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-clarity-ad-ole-sub-studies\">Clinical Evidence \u2013 Clarity AD OLE Sub\u2011Studies<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>SC\u2011AI 500\u202fmg Weekly<\/th><th>IV 10\u202fmg\/kg Bi\u2011Weekly<\/th><th>Comparison<\/th><\/tr><\/thead><tbody><tr><td><strong>Pharmacokinetic Exposure<\/strong><\/td><td>Equivalent<\/td><td>Standard<\/td><td><strong>Non\u2011inferior<\/strong><\/td><\/tr><tr><td><strong>Amyloid Clearance<\/strong><\/td><td>Similar<\/td><td>Standard<\/td><td>Comparable<\/td><\/tr><tr><td><strong>Clinical Efficacy (CDR\u2011SB)<\/strong><\/td><td>Maintained<\/td><td>Standard<\/td><td>Comparable<\/td><\/tr><tr><td><strong>Infusion\/Injection Reactions<\/strong><\/td><td>&lt;2\u202f%<\/td><td>12\u201115\u202f%<\/td><td><strong>Favorable<\/strong><\/td><\/tr><tr><td><strong>Patient Convenience<\/strong><\/td><td>Home administration<\/td><td>Clinic required<\/td><td><strong>Significant advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Impact:<\/strong> Eliminates <strong>bi\u2011weekly clinic visits<\/strong> (26 visits\/year \u2192 52 home injections\/year), reducing caregiver burden and improving adherence<\/li>\n\n\n\n<li><strong>Caregiver Benefit:<\/strong> <strong>Autoinjector design<\/strong> simplifies administration vs. IV infusion setup<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Early AD Patients<\/strong><\/td><td>8.5\u202fmillion<\/td><td>8.8\u202fmillion<\/td><td>9.1\u202fmillion<\/td><\/tr><tr><td><strong>LEQEMBI IV Market Share<\/strong><\/td><td>18\u202f%<\/td><td>22\u202f%<\/td><td>25\u202f%<\/td><\/tr><tr><td><strong>SC\u2011AI Uptake (if approved)<\/strong><\/td><td>0\u202f%<\/td><td>35\u202f% of new patients<\/td><td>55\u202f% of total<\/td><\/tr><tr><td><strong>Annual US Price (SC\u2011AI)<\/strong><\/td><td>\u2013<\/td><td>$26,500<\/td><td>$26,500<\/td><\/tr><tr><td><strong>Eisai\/Biogen Revenue (LEQEMBI)<\/strong><\/td><td>$1.1\u202fbillion<\/td><td>$1.8\u202fbillion<\/td><td>$2.4\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Donanemab<\/strong> (Eli Lilly) \u2013 IV infusion only; no SC formulation in development<\/li>\n\n\n\n<li><strong>Kisunla<\/strong> (Eli Lilly) \u2013 Similar IV requirement<\/li>\n\n\n\n<li><strong>LEQEMBI IQLIK<\/strong> \u2013 <strong>First and only SC anti\u2011amyloid therapy<\/strong> with home administration option<\/li>\n\n\n\n<li><strong>Market Expansion:<\/strong> SC formulation expected to <strong>accelerate patient enrollment<\/strong> by 30\u201140\u202f% due to convenience advantage<\/li>\n\n\n\n<li><strong>Reimbursement:<\/strong> CMS coverage already established for IV; SC expected to qualify for <strong>same billing codes<\/strong> with <strong>additional home health benefit<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Eisai\u2019s <strong>Indianapolis facility<\/strong> will produce SC formulation; <strong>autoinjector device<\/strong> supplied by <strong>Ypsomed<\/strong><\/li>\n\n\n\n<li><strong>Launch Readiness:<\/strong> <strong>Q3\u202f2026 US launch<\/strong> anticipated upon approval; <strong>EU filing<\/strong> planned for <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Patient Support:<\/strong> <strong>LEQEMBI CarePath<\/strong> program will provide <strong>home nursing training<\/strong> for SC administration<\/li>\n\n\n\n<li><strong>Patent Extension:<\/strong> New formulation extends <strong>market exclusivity<\/strong> to <strong>2032<\/strong> (vs. 2030 for IV)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FDA approval timelines, commercial adoption rates, and revenue forecasts for LEQEMBI IQLIK. Actual results may differ due to regulatory review outcomes, competitive dynamics, and reimbursement policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,350,38,993,1151],"class_list":["post-55500","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biogen","tag-eisai","tag-market-approval-filings","tag-nasdaq-biib","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55500\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing\" \/>\n<meta property=\"og:description\" content=\"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55500\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T12:40:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T12:40:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai\\\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing\",\"datePublished\":\"2026-01-26T12:40:46+00:00\",\"dateModified\":\"2026-01-26T12:40:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"Eisai\",\"Market approval filings\",\"NASDAQ: BIIB\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55500#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55500\",\"name\":\"Eisai\\\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T12:40:46+00:00\",\"dateModified\":\"2026-01-26T12:40:47+00:00\",\"description\":\"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55500\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55500#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai\\\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing - Insight, China&#039;s Pharmaceutical Industry","description":"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55500","og_locale":"en_US","og_type":"article","og_title":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing","og_description":"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.","og_url":"https:\/\/flcube.com\/?p=55500","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T12:40:46+00:00","article_modified_time":"2026-01-26T12:40:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55500#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55500"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing","datePublished":"2026-01-26T12:40:46+00:00","dateModified":"2026-01-26T12:40:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55500"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","Eisai","Market approval filings","NASDAQ: BIIB","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55500#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55500","url":"https:\/\/flcube.com\/?p=55500","name":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T12:40:46+00:00","dateModified":"2026-01-26T12:40:47+00:00","description":"Eisai Co., Ltd. (TYO:\u202f4523) and Biogen Inc. (NASDAQ:\u202fBIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab\u2011irmb) subcutaneous autoinjector (SC\u2011AI) \u2013 branded LEQEMBI IQLIK \u2013 as a once\u2011weekly starting dose for early Alzheimer\u2019s disease, with a PDUFA action date of May\u202f24,\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55500#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55500"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55500#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai\/Biogen\u2019s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer\u2019s Dosing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55500"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55500\/revisions"}],"predecessor-version":[{"id":55501,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55500\/revisions\/55501"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}